Teriparatide treatment of osteoporosis in solid organ transplant recipients—a single-center experience
Talia Diker Cohen, Ilana Shraga-Slutzky, Keren Kaminer, Alexander Gorshtein, Idit Dotan, Gloria Tsvetov · 2026
Read Teriparatide treatment of osteoporosis in solid organ transplant recipients—a single-center experience by Talia Diker Cohen, Ilana Shraga-Slutzky, Keren Kaminer, Alexander Gorshtein, Idit Dotan, Gloria Tsvetov (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13538171.txt.
Description
Talia Diker Cohen and co-authors report bone drug care for organ transplant patients with weak bones at one center, in a study from 2026. Transplant patients face high fracture risk from organ strain and long term immune drugs, yet growth type bone drugs had thin proof in this group.
Thirty nine kidney, lung, and liver recipients took the drug for a median span near two years. Bone density rose at the spine, hip neck, and total hip by clear amounts. New fractures were few during care and more after care stopped. One high calcium case ended care, and grafts showed no harm.
Catalog record
| CREATOR | Talia Diker Cohen, Ilana Shraga-Slutzky, Keren Kaminer, Alexander Gorshtein, Idit Dotan, Gloria Tsvetov |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |